Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 15;203(12):1453-1455.
doi: 10.1164/rccm.202104-0850ED.

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis

Cori L Daines  1 , Wayne J Morgan  1
Affiliations
Editorial

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis

Cori L Daines et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of two potential treatment responses. Treatment A acutely improves FEV1 but does not slow rate of decline in FEV1, resulting in a minor improvement in the long-term outcome. Treatment B does not acutely improve FEV1 but does slow the rate of decline in FEV1, resulting in sustained benefit.
See this image and copyright information in PMC

Comment on

References

    1. Ranganathan SC, Hall GL, Sly PD, Stick SM, Douglas TA. AREST-CF. Early lung disease in infants and preschool children with cystic fibrosis. Am J Respir Crit Care Med. 2017;195:1567–1575. - PMC - PubMed
    1. Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, et al. Early life growth trajectories in cystic fibrosis are associated with pulmonary function at age 6 years. J Pediatr. 2015;167:1081–8.e1. - PMC - PubMed
    1. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. VX18-445-106 Study Group. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203:1522–1532. - PMC - PubMed
    1. Heijerman HGM, KcKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Study Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial. Lancet. 2019;394:1940–1948. - PMC - PubMed
    1. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809–1819. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources